PHARMACEUTICAL COMPOSITIONS TO ENHANCE PHAGOCYTOSIS WITHOUT INFLAMMATION

1 . A pharmaceutical composition comprising a peptide and an immunotherapeutic composition comprising a viral vector and a nucleic acid sequence encoding an antigen;

wherein the peptide is 3 to 24 amino acid residues in length and comprises a striapathic region consisting of alternating hydrophilic and hydrophobic modules;

wherein each hydrophilic module consists of from 1 to 5 hydrophilic amino acid residues; and

wherein each hydrophobic module consists of from 1 to 5 hydrophobic amino acid residues.

2 . The pharmaceutical composition of claim 1 , wherein the viral vector is a replication defective adenovirus vector comprising a deletion in an E2b region of the replication defective adenovirus vector and a nucleic acid sequence encoding an antigen.

3 . The pharmaceutical composition of claim 1 , wherein the antigen is selected from the group consisting of a cancer associated antigen and an infectious disease associated antigen.

4 . The pharmaceutical composition of claim 2 , wherein the replication defective adenovirus vector further comprises a deletion in an E1 region of the replication defective adenovirus vector, a deletion in an E3 region of the replication defective adenovirus vector, a deletion in an E4 region of the replication defective adenovirus vector, or a combination thereof.

5 . A method of inducing phagocytosis without inflammation, comprising administering to a subject in need thereof,

a) an immunotherapeutic composition comprising a viral vector and a nucleic acid sequence encoding an antigen; and

b) peptide, wherein the peptide is 3 to 24 amino acid residues in length and comprises a striapathic region consisting of alternating hydrophilic and hydrophobic modules,

wherein each hydrophilic module consists of from 1 to 5 hydrophilic amino acid residues; and

wherein each hydrophobic module consists of from 1 to 5 hydrophobic amino acid residues.

6 . The method of claim 5 , wherein the viral vector is a replication defective adenovirus vector comprising a deletion in an E2b region of the replication defective adenovirus vector and a nucleic acid sequence encoding an antigen.

7 . The method of claim 6 , wherein the antigen is selected from the group consisting of a cancer associated antigen and an infectious disease associated antigen.

8 . The method of claim 6 , wherein the replication defective adenovirus vector further comprises a deletion in an E1 region of the replication defective adenovirus vector, a deletion in an E3 region of the replication defective adenovirus vector, a deletion in an E4 region of the replication defective adenovirus vector, or a combination thereof.

9 . A method of inducing phagocytosis, comprising administering to a subject in need thereof,

a) a composition comprising a yeast lysate prepared from a yeast; and

b) an immunotherapeutic composition comprising a viral vector and a nucleic acid sequence encoding an antigen.

10 . The method of claim 9 , wherein the method of inducing phagocytosis does not cause inflammation.

11 . The method of claim 9 , wherein the yeast lysate lacks yeast membranes and yeast cell walls.

12 . The method of claim 9 , wherein the yeast lysate comprises intact yeast.

13 . The method of claim 9 , wherein the yeast is heat-inactivated.

14 . The method of claim 9 any of claims 9 13 , wherein the yeast is selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces carlsbergensis, Candida albicans, Candida kefyr, Candida tropicalis, Cryptococcus laurentii, Cryptococcus neoformans, Hansenula anomala, Hansenula polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Kluyveromyces marxianus var. lactis, Pichia pastoris, Rhodotorula rubra, Schizosaccharomyces pombe, and Yarrowia lipolytica.

15 . The method of claim 14 , wherein the yeast is Saccharomyces cerevisiae.

16 - 19 . (canceled)

20 . The method of claim 9 , wherein the compositing further comprises a peptide, wherein the peptide is 3 to 24 amino acid residues in length and comprises a striapathic region consisting of alternating hydrophilic and hydrophobic modules, wherein each hydrophilic module consists of from 1 to 5 hydrophilic amino acid residues; and

wherein each hydrophobic module consists of from 1 to 5 hydrophobic amino acid residues.

21 . The method of claim 9 , wherein the antigen is selected from the group consisting of a cancer associated antigen and an infectious disease associated antigen.

22 - 32 . (canceled)